Genmab A/S (NASDAQ: GMAB) announced that its phase 3 EPCORE FL-1 trial met dual primary endpoints for treating relapsed/refractory follicular ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE